The Werner Group - Biotech Solutions

The Werner Group helps your

company:

Analyze and assess the effect of legislative and regulatory developments as well as bioethics issues on your company or organization
Create and execute a strategic plan to maximize your impact on policy issues
Establish and manage essential Washington relationships
Position your organization on issues that impact your success
Form strategic alliances with other companies and in the advocacy community

"Michael Werner's seasoned skill in finding innovative solutions that work for the biotech industry is remarkable."

--Rob Chess, Chairman, Nektar Therapeutics

"The Werner Group consistently delivers top-notch advice and analysis."

- Tom Amick, Chairman and CEO, Aldagen.

"Michael tackles tough issues with substantive expertise and an ability to bring people together to develop solutions"

--Dan Perry, Executive Director, Alliance for Aging Research

"Michael Werner led our successful advocacy efforts in Congress and with the Bush Administration. His leadership, skill, and political expertise were key to our victory."

-- Tom Bognanno, President and CEO, Community Health Charities.

"The Werner Group brings you the Washington political savvy you need to meet your goals."

--Una Ryan, CEO, AVANT Immunotheraputics

What's NEW?

Michael will be a Presenter at the following:

March 6, 2008

Hofstra Law School

Hempstead, NY

May 15, 2008

Internal Medicine 2008,

Washington DC

June 17-20, 2008

BIO International Convention,

San Diego CA

The Werner Group brings power to

your team:

More than 20 years of Washington health care legislative, regulatory, and legal experience
Thorough understanding of bioethics issues
A network of seasoned professionals to meet all your advocacy and policy needs
Insight into how Washington policies affect biotech companies and other health care organizations
Excellent relationships with BIO leadership, allowing you to maximize this powerful asset

The Werner Group is led by Michael J. Werner, Esq.

Werner is a well-respected advisor and advocate on national issues for biotechnology and pharmaceutical companies, health care providers, and others.

He has served as Chief of Policy for BIO which represents more than 1000 biotech companies in the US and around the world. He was responsible for issues including: FDA review and approval processes for biotech products, reimbursment/CMS policies, intellectual property, and bioethics.

NEW ARTICLES

New Lobbying Strategy: Stall?”

The Politico,

January 16, 2008

“FDAAA: The Challenges Ahead”,

SCRIP World Pharmaceutical News,

December 2007

"California, Here We Come",

The Journal of Life Sciences,

October 1, 2007.